Literature DB >> 11252346

Non-specific immunotherapy with bacille Calmette-Guérin (BCG).

A P van der Meijden.   

Abstract

Mesh：

Year:  2001        PMID： 11252346      PMCID： PMC1905988          DOI： 10.1046/j.1365-2249.2001.01449.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  10 in total

1.  Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

Authors:  Y Luo; X Chen; R Han; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

2.  Immunopotentiation with BCG. I. Immune response to different strains and preparations.

Authors:  G B Mackaness; D J Auclair; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

3.  Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis.

Authors:  B Zbar; I D Bernstein; G L Bartlett; M G Hanna; H J Rapp
Journal:  J Natl Cancer Inst       Date:  1972-07       Impact factor: 13.506

Review 4.  Intravesical chemotherapy and immunotherapy: how do we assess their effectiveness and what are their limitations and uses?

Authors:  D L Lamm; A P van der Meijden; H Akaza; C Brendler; P O Hedlund; Y Mizutani; T L Ratliff; M R Robinson; T Shinka
Journal:  Int J Urol       Date:  1995-06       Impact factor: 3.369

5.  Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.

Authors:  H W Herr
Journal:  Br J Urol       Date:  1997-11

6.  A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer.

Authors:  A Pawinski; R Sylvester; K H Kurth; C Bouffioux; A van der Meijden; M K Parmar; L Bijnens
Journal:  J Urol       Date:  1996-12       Impact factor: 7.450

7.  Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.

Authors:  E C De Boer; W H De Jong; P A Steerenberg; L A Aarden; E Tetteroo; E R De Groot; A P Van der Meijden; P D Vegt; F M Debruyne; E J Ruitenberg
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

9.  A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group.

Authors:  J A Witjes; A P vd Meijden; W P Witjes; W Doesburg; H E Schaafsma; F M Debruyne
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

10.  Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.

Authors:  T M de Reijke; E C de Boer; K H Kurth; D H Schamhart
Journal:  J Urol       Date:  1996-02       Impact factor: 7.450
  10 in total
  5 in total

1.  Prostaglandin E2 down-regulates viable Bacille Calmette-Guérin-induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro.

Authors:  H Yamada; E Kuroda; S Matsumoto; T Matsumoto; T Yamada; U Yamashita
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 2.  Ayurveda Rasayana as antivirals and immunomodulators: potential applications in COVID-19.

Authors:  Rajeshwari Singh; Sumeet Goel; Pascale Bourgeade; Lotfi Aleya; Devesh Tewari
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-07       Impact factor: 5.190

3.  Local immune and microbiological responses to mucosal administration of a Liposome-TLR agonist immunotherapeutic in dogs.

Authors:  William Wheat; Lyndah Chow; Alana Kuzmik; Sirikul Soontararak; Jade Kurihara; Michael Lappin; Steven Dow
Journal:  BMC Vet Res       Date:  2019-09-13       Impact factor: 2.741

Review 4.  Botanical immunodrugs: scope and opportunities.

Authors:  Bhushan Patwardhan; Manish Gautam
Journal:  Drug Discov Today       Date:  2005-04-01       Impact factor: 7.851

Review 5.  Rasayans and non-rasayans herbs: Future immunodrug - Targets.

Authors:  Gaurav Mahesh Doshi; Hemant Devidas Une; Pradnya Palekar Shanbhag
Journal:  Pharmacogn Rev       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.